Search - tctmd.com

Displaying 21 - 40 of 48

Sort: Relevancy | Date

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

Cumulative Burden of LDL Cholesterol Increases CHD Risk

Michael O'Riordan

September 23, 2021

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

News Daily News

Genetic Testing for CVD in Children: AHA Statement Suggests Focus on Multidisciplinary Care

Yael L. Maxwell

September 01, 2021

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

Shelley Wood

December 23, 2020

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2020

Shelley Wood

March 02, 2020

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Michael O'Riordan

May 15, 2019

News Daily News

Updated AHA Scientific Statement Addresses CV Risk Reduction in High-Risk Youth

Todd Neale

March 05, 2019

News Daily News

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

Yael L. Maxwell

June 25, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Yael L. Maxwell

March 28, 2018

Advertisement

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

British Medical Groups Express Concern About Inclisiran Rollout

Cumulative Burden of LDL Cholesterol Increases CHD Risk

Heterozygous FH Diagnosed Late, Remains Undertreated

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Genetic Testing for CVD in Children: AHA Statement Suggests Focus on Multidisciplinary Care

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

TCTMD’s Top 10 Most Popular Stories for February 2020

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Updated AHA Scientific Statement Addresses CV Risk Reduction in High-Risk Youth

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

Alirocumab Price Slashed in Deal With Express Scripts

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content